Natural vitamin e pill may delay liver transplant in cirrhosis patients
NCT ID NCT02581085
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether a natural vitamin E supplement called tocotrienol can slow the worsening of end-stage liver disease. Seventy adults with stable but advanced liver disease (MELD score 8–17) will take either tocotrienol or a placebo twice daily for three years. The main goal is to see if the supplement prevents a rise in the MELD score, which measures liver function and predicts transplant need.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tocotrienol (a natural vitamin E supplement)
What this could lead to
If it works, this could provide a simple, safe supplement to slow liver damage and delay the need for a transplant in people with end-stage liver disease.
What could go wrong
This is a small, early-phase trial (70 people) testing a supplement against a placebo. Previous results need confirmation, and the supplement may not slow disease progression or prevent serious complications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END STAGE LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
IU Health Unviersity Hospital
Indianapolis, Indiana, 46202, United States